Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bimosiamose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP known ✓ | P16109 | 2/20 | 1.00 |
| ▸ | SELPLG | Q14242 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bimosiamose SCHEMBL14970212 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL12182030 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL14015902 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL29367817 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL26341832 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL29372538 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL7614341 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL7620761 | 1.00 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL2528669 | 0.99 | SELP (0.98) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL8205205 | 0.99 | SELP (0.98) | SELPSELPLGPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010115164-A1 | TOPICAL COMPOSITIONS | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2010-10-07 | — | — | WO | claimed |
| US-20020132220-A1 | Use of selectin antagonists in organ preservation solutions | TEXAS BIOTECHNOLOGY CORPORATION | 2002-09-19 | — | — | US | claimed |
| EP-0840606-B1 | DI- AND TRIVALENT SMALL MOLECULE SELECTIN INHIBITORS | TEXAS BIOTECHNOLOGY CORP (US) | 2000-06-07 | — | — | EP | claimed |
| US-5919768-A | COMPOUNDS WHICH INHIBIT BINDING OF SELECTINS TO SIALYL-LEWIS-X AND SIALYL-LEWIS-A CARBOHYDRATES | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-07-06 | — | — | US | claimed |
| US-20140363507-A1 | DENTRIC POLYGLYCEROL SULFATES AND SULFONATES AND THEIR USE FOR INFLAMMATORY DISEASES | FREIE UNIVERSITAT BERLIN (DE) | 2014-12-11 | — | — | US | disclosed |
| EP-2607368-A1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane | Revotar Biopharmaceuticals AG (DE) | 2013-06-26 | — | — | EP | disclosed |
| EP-2607368-A1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane | Revotar Biopharmaceuticals AG (DE) | 2013-06-26 | — | — | EP | disclosed |
| EP-2607368-A1 | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane | Revotar Biopharmaceuticals AG (DE) | 2013-06-26 | — | — | EP | disclosed |
| EP-2089407-B1 | CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL]HEXANE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-05-22 | — | — | EP | disclosed |
| EP-2089407-B1 | CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL]HEXANE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-05-22 | — | — | EP | disclosed |
| EP-2566580-A1 | PROCESS FOR THE PREPARATION OF BIMOSIAMOSE | Revotar Biopharmaceuticals AG (DE) | 2013-03-13 | — | — | EP | disclosed |
| US-20120328519-A1 | DENTRIC POLYGLYCEROL SULFATES AND SULFONATES AND THEIR USE FOR INFLAMMATORY DISEASES | FREIE UNIVERSITAT BERLIN (DE) | 2012-12-27 | — | — | US | disclosed |
| EP-1897533-A1 | Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions | Revotar Biopharmaceuticals AG (DE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008015015-A2 | DENDRITIC POLYGLYCEROL SULFATES AND SULFONATES AND THEIR USE FOR INFLAMMATORY DISEASES | FREIE UNIVERSITÄT BERLIN (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20070276036-A1 | Non-Glycosidic and Non-Peptidic Select Inhibitors, and the Use Thereof | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2007-11-29 | — | — | US | disclosed |
| EP-1778625-A1 | NON-GLYCOSIDIC AND NON-PEPTIDIC SELECT INHIBITORS, AND THE USE THEREOF | Johannes Gutenberg-Universität Mainz (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006010598-A1 | NON-GLYCOSIDIC AND NON-PEPTIDIC SELECT INHIBITORS, AND THE USE THEREOF | Johannes Gutenberg-Universität Mainz (DE) | 2006-02-02 | — | — | WO | disclosed |
| US-20020132220-A1 | Use of selectin antagonists in organ preservation solutions | TEXAS BIOTECHNOLOGY CORPORATION | 2002-09-19 | — | — | US | disclosed |
| EP-0840606-B1 | DI- AND TRIVALENT SMALL MOLECULE SELECTIN INHIBITORS | TEXAS BIOTECHNOLOGY CORP (US) | 2000-06-07 | — | — | EP | disclosed |
| US-5919768-A | COMPOUNDS WHICH INHIBIT BINDING OF SELECTINS TO SIALYL-LEWIS-X AND SIALYL-LEWIS-A CARBOHYDRATES | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276036-A1 | Non-Glycosidic and Non-Peptidic Select Inhibitors, and the Use Thereof | VCAM1, ICAM1, SELPLG | SELP 5/4885SELPLG 3/4885PPARG 3821/4885 |
| US-20020132220-A1 | Use of selectin antagonists in organ preservation solutions | SELE, SELPLG, SELL | SELP 4/4885SELPLG 2/4885PPARG 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.